Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dino's Bar & Grill -- Ignore unavailable to you. Want to Upgrade?

To: Goose94 who wrote (90102)	7/14/2020 9:55:53 AM
From: Goose94	Read Replies (1) \| Respond to of 202922

Lexagene Holdings (LXG-V) Industrial Alliance Securities analyst Chelsea Stellick upgraded Lexagene Holdings "buy" from "speculative buy" after the company on Monday unveiled its commercial product, MiQLab, that tests for "SARS-CoV-2." Ms. Stellick says the "milestone achievement," which involves a commercial date of late this summer and manufacturing plans, has boosted her valuation of the stock. Accordingly, Ms. Stellick raised her price target to $1.70 from $1.05. Analysts on average target the shares at $1.61. Ms. Stellick had commenced coverage on Lexagene Holdings with a "speculative buy" call and a $1 share target. Ms. Stellick was the lone analyst covering the stock. Ms. Stellick said she saw "ample upside as the commercial roll-out gains traction." The shares could then be had for 85 cents.